Cookies are essential for the operation of our website. By using our website, you agree to the use of cookies.
This website uses cookies to improve and personalize content, and for tracking and analytics. By clicking "Accept All Cookies", you are providing consent for Exelixis to collect and retain personal data for Exelixis to optimize the use of this website. You can learn more about Exelixis' use of cookies by reviewing Exelixis' Privacy Statement.
Reject Nonessential Cookies Accept All Cookies
Skip to main content

Disable motion

Explore
Our Pipeline

We are building a robust and diverse oncology pipeline through discovery and collaboration efforts. Our focus is on targets with novel and promising MOAs and next-generation approaches, including both small molecules and biologics.
Molecular structures shown are artistic renderings.

Zanzalintinib (XL092): TKI

An oral tyrosine kinase inhibitor (TKI) shown in mouse xenograft models to target VEGFR, MET, the TAM kinases (TYRO3, AXL, and MER), and other kinases implicated in the growth and spread of cancer.
Click to go to Resource

XB002: TF-MTI ADC

A rationally designed antibody-drug conjugate (ADC) using a novel auristatin-based microtubule inhibitor payload (MTI) shown in human xenograft models to target tissue factor (TF).
Click to go to Resource

XL309: USP1 Inhibitor

An orally bioavailable and selective small molecule shown in mouse xenograft models to inhibit ubiquitin-specific peptidase 1 (USP1), a deubiquitinase that facilitates DNA damage repair.
Click to go to Resource